TNF -a blockade therapy. Among the several variants that may determine the result of the treatment, TNF-a gene polymorphism has been suggested to play an important role (6) . The TNF-a gene is located within the class III region of the major histocompatibility complex, between the HLA-B and the HLA-DRB I genes. TNF-a gene contains many polymorphisms including single nucleotide polymorphism (SNP). It has been suggested that an SNP in the human TNF-a gene promoter, the -308 G/A variant, may be relevant for the response to the TNF-a inhibitors (7, 8) . This variant of the TNF-a gene has been chosen because this SNP may cause inter-individual variability in the magnitude of the secretor response to TNF-a (9) . Moreover, variants of the -308 SNPs are linked to an enhanced severity of RA (10) . Besides TNF-a, High Mobility Group Box-I (HMGB-I), a nuclear DNA binding protein, was rediscovered as a new pro-inflammatory cytokine (11) . HMGB-I is released from necrotic cells and/ or secreted from activated macrophages (II), it has been identified as a mediator of endotoxin lethality (12) and a causative factor in arthritis (13) (14) (15) acting at least as a pro-inflammatory cytokine (16) (17) (18) (19) . The aim of this study was to investigate whether the -308 G/A variant of the TNF-a gene is associated with an altered expression of HMBG-I.
MATERIALS AND METHODS

Patients
A total of 110 consecutive patients with rheumatoid arthritis RA (n= 50, 39 female, II male) and spondyloarthritis SpAs (n= 60, 20 female, 40 male) diagnosed according to the American College of Rheumatology, modified New York criteria for ankylosing spondylitis (AS) and Moll and Wright criteria for psoriatic arthritis (PA), and referring to the Rheumatology Unit of Messina University Hospital were enrolled (from January to July 2011). Informed consent was obtained from all the subjects or their legal representative. All patients were Caucasian, born and resident in Southern Italy. For rheumatoid arthritis patients and PA, peripheral arthritis variant, the modified disease activity score (DAS 28) was used, while for SpAs Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used (20, 21) . The response to therapy was determined by the change in DAS28 and BASDAI, observed after 24 weeks. The protocol complied with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Messina University Hospital.
Genotypingfor -308 G/A polymorphism
Genomic DNA was isolated from whole blood, cells were lysed in DNA buffer containing 10 mM Tris-HCI pH 7.4, 100 mM NaCI, 1 mM EDTA, 1 mM MgCI 2 • After centrifugation nuclei were lysed by the combined action of 10% SDS and proteinase K at 37°C overnight. The cell debris from lysis, mainly protein, were captured by the organic solvents phenol and chloroform, DNA was washed with 70% ethanol and resuspended in an adequate volume of RNAse/DNAse free water. DNA concentration in each sample was spectrophotometrically determined and stored for genotyping assay. Genotypes were determined with the use of allele-specific oligonucleotide probes (TaqMan assay C_75 14879_10, Applied Biosystems) on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA).
HMGB-I and TNF-a. mRNA quantification
HMGB-I and TNF-a mRNA was quantified as previously described (22) . Briefly total RNA was extracted from leukocytes obtained from whole blood, and after reverse transcription cDNA was stored at -80°C and was used to quantify the amount ofHMGB-l and TNF-a by real-Time Polimerase Chain Reaction method (Real-Time RT-PCR) as well as b-actin cDNA as endogenous control. The results of the target genes were expressed as an n-fold difference relative to the endogenous control gene (relative expression levels).
Western blot analysis for plasma HMGB-I
Protein samples (30 ug) were denatured in reducing buffer (62 mM Tris pH 6.8, 10% glycerol, 2% SDS, 5%~-mercaptoethanol, 0.003% bromophenol blue) and separated by electrophoresis on an SDS (12%) polyacrylamide gel. The separated proteins were transferred on to a nitrocellulose membrane using transfer buffer (39 mM glycine, 48 mM Tris, pH 8.3, 20% methanol) at 200 rnA for 1 h. The membranes stained with Ponceau's (0.005% in 1% acetic acid) to confirm equal amounts of protein were blocked with 5% non-fat dry milk in TBS-O.l % Tween for 1 h at room temperature, washed three times for 10 min each in TBS-0.1% Tween, and incubated with a primary antibody for HMGB-l (Abeam, Cambridge, UK) in TBS-O.l% Tween overnight at 4°C. After being washed three times for 10 min each in TBS-O.l % Tween, the membranes were incubated with a secondary antibody peroxidaseconjugated goat anti-rabbit immunoglobulin G (Pierce, Rockford, Illinois, USA) for I h at room temperature. After washing, the membranes were analyzed by the enhanced chemiluminescence system according to the manufacture's protocol (Amersham, Little Chalfont, UK). The HMGB-l protein signal was quantified by scanning densitometry using a bio-image analysis system (Bio-Profil Celbio, Milan, Italy). Equal loading of protein was assessed on stripped blots by immunodetection of -actin with a rabbit monoclonal antibody (Cell Signaling, Beverly, Massachusetts) and peroxidase-conjugated goat anti-rabbit immunoglobulin G (Pierce, Rockford, Illinois). All antibodies are purified by protein A and peptide affinity chromatography.
Quantification ofTNF-a by Enzyme-LinkedImmunosorbent Assay (ELISA)
Serum TNF-u level was measured using a sandwich enzyme-linked immunosorbent assay (Bio-Source, Nivelles, Belgium), according to the manufacturer's instructions.
Statistical analysis
Patients were subdivided into group A (GIA genotype) and group G (GIG genotype). The results were expressed as mean ± SD. Normal distribution of data was tested with Skewness and Kurtosis tests for normality which showed normal distribution. Data were analyzed by one-way and two-way ANOYA where appropriate. Linear regression analysis for the goodness-of-fit was used to determine r values for HMGB-I levels. Association analyses of treatment response and HMGB-I expression with the -308TNF -u polymorphism were carried out by the c 2 test. Responsiveness to the treatment was calculate, according to the response criteria for each group, using t-test for independent samples.
Univariate and multivariate analyses were applied to test possible influences of specific allelic variants on HMGB-l and TNF-u expression and circulating levels; disease status, gender, concomitant therapies, age and age at disease onset were inserted as covariates. Haploview 3.2 was used to test -308 genotype for Hardy-Weinberg equilibrium. The level for statistical significance was set at p<0.05, all statistics were done with software package SPSS version 12.0.
RESULTS
Disease status and demographics of rheumatoid arthritis and spondyloarthritis subjects are reported in Table I . A total of 60.9% of the patients were women. Mean ± SD age was 54±11 years and the mean disease duration was 16.7±10.6 years. Patients were treated with stable dosages of prednisolone, other Disease Modifying Anti-Rheumatic Drugs (DMARDs) co-medication, together with anti TNF-a agent. Fig. I shows the distribution of patients according to the -308 genotype. All patients had comparable disease activity as evidenced by the mean DAS28 and BASDAI. However, when disease activity was analyzed in the different subgroups (GIG and GIA) a clear cut difference was observed in the G/A group (p<0.05 vs GIG; Table I) had the GIG genotype and 17 (15.5%) had the G/A genotype. No patient showed the AlA genotype. The clinical severity of the disease was linked with the G/A variant of the -308TNF-a gene allele. Increased severity was predominantly associated with the GIA genotype, while lower disease score was seen in patients with the GIG genotype (Tables II and III ). In RA and SpAs patients, 24 weeks from the beginning of the anti-TNF-a treatment, the responsiveness, according to DAS28 and BASDAI criteria, was significantly different in the two group (Tables II  and III) . TNF-a mRNA expression was significantly higher in patients with the GIA compared to the GIG genotype ( Fig. 2A) . G/A patients had also increased circulating levels of TNF-a (Fig. 2B ). HMGB-1 mRNA expression was augmented in subjects carrying the GIA genotype compared to the other group (Fig. 2C) . Markedly increased circulating levels of the HMGB-l protein were also observed in the subjects with the GIA genotype compared to the other group (Fig. 2D ). Multivariate analysis showed that the significantly increased expression of both TNF-a (r 2=0.83) and HMGB-l (r 2=0.82) in patients carrying the GIA genotype was irrespective of age, treatment, disease duration, and gender.
DISCUSSION
The last ten years have seen a better understanding of the pathogenesis of rheumatoid arthritis and studies have led to the recognition of TNF-a as one of the cornerstone cytokines involved in the synovial inflammatory process. Such results have provided the basis for the development of TNF-a blockers for the treatment of rheumatoid arthritis. However, TNF-a blockers are efficient in about 70% of patients, but 30% are resistant. A systematic review of the literature and meta-analysis clearly indicated that poor responsiveness to TNF-a blockade therapy might be due to polymorphism at position -308 of the TNF-a gene, the GIA genotype patients being less responsive to anti-TNF-a agent than patients carrying the GIG genotype (23) . Accordingly, our study population showed a distribution of this allele similar to other studies and an increased disease score in the GIA genotype. The reason for the clear cut difference, in responsiveness, may be due to the fact that GIA allele and, particularly the rare AlA allele, are associated with inter-individual variability in the magnitude of the secretor response to TNF-a (9) . More specifically, it can be hypothesized that rheumatoid arthritis patients have a poor response to the TNF-a blockade therapy because of the enhanced expression of this cytokine. In agreement with this hypothesis, our results show that patients carrying the GIA genotype have enhanced mRNA expression of TNF-a and augmented circulating levels of the cytokine compared to the patients with the GIG genotype. Furthermore, our patients carrying the GIA genotype have an increased disease severity. However, the present data are, at least in part, in disagreement with previous findings in an Egyptian population, showing that RA female patients carrying the AIA and A/G genotype have an enhanced susceptibility to the disease, but a reduced disease severity (24) .
HMGB-l protein is another late inflammatory cytokine that has been implicated in pathology of a wide variety of diseases, including RA (13) (14) (15) . Because of its pivotal role in the pathogenesis of RA (25) , it has been indicated as an ideal target for innovative therapeutic approaches to the treatment of this autoimmune disease. We therefore investigated the expression ofHMGB-l protein in our patients and we correlated it with the -308 TNF-a polymorphism. Interestingly, irrespective of the underlying disease and treatment, patients carrying the GIA genotype had enhanced HMGB-l protein mRNA levels and increased circulating concentration of this late inflammatory cytokine compared to patients with GIG genotype. This evidence led us to hypothesize that the reported poor responsiveness to the anti TNF-a blockers of the patients carrying the GIA genotype, as well as their increased enhanced susceptibility to and severity ofRA and SpAs, might be due, at least in part, to an exaggerated expression and production of the HMGB-l protein. Indeed the multivariate analysis showed that the increase in HMGB-l and TNF-a gene expression and protein levels are due only to the GIA genotype, at least in our population; in fact, all the variables inserted in our model did not alter this relationship. Two hypotheses can be drawn, at the moment, to explain this interesting finding. It has been suggested that there is a tight cross-talk between HMGB-l protein and TNF-a: more specifically the HMGB-l protein stimulates the synthesis and the release of TNF-a (26) however, the opposite may hold also true as TNF-a induces the production of the HMGB-l protein (27) . Therefore, the enhanced expression of HMGB-l protein observed in patients carrying the GIA genotype might be a direct consequence ofenhanced stimulatory effects ofTNF-a on this late cytokine. Alternatively an additional genetic inter-individual variation might concur to the variability in the HMGB-l expression. In fact, the human gene consists of 5 exons, and is located on the short chromosome 13 (28) . The presence of several polymorphic loci throughout the gene has been proposed (29) , and, in a recent study of patients with systemic inflammatory response syndrome (SIRS) admitted to an intensive care unit, the presence ofthe -1377 delA and 982C>T polymorphisms has been shown to represent significant risk factor for late and early mortality, respectively (30). Therefore, in light of this observation, the occurrence might also be speculated of an association between polymorphisms in the genes for TNF-a and HMGB-l that may account for an increased magnitude in the expression of the two inflammatory cytokines and, probably, for the poor response to the anti-TNF-a blockade therapy. At present this is only a scientific challenge that needs to be addressed using retrospective and prospective studies to explore whether this pharmacogenetic approach may guide the interpretation of our results. Exploring this scientific hypothesis could be also extremely intriguing for a better understanding of the genetic causes responsible for the poor responsiveness to TNF-a blockade therapy observed in an elevated percentage of rheumatoid arthritis patients.
In conclusion, our observation shows that rheumatoid arthritis patients carrying the GIA genotype have enhanced HMGB-l and TNF-a mRNA levels and increased circulating concentration of the inflammatory cytokines compared to patients with GIG genotype. The increased expression of HMGB-I might contribute to determine the poor responsiveness to the anti TNF-a agents. It remains to be clarified whether an additional polymorphism in the HMGB-I gene may be responsible for this finding.
